Acme Laboratories
Acme Laboratories is a Bangladesh-based pharmaceutical manufacturer and a member of the ACME Group of Companies.
Last updated August 31, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Acme Laboratories is a pharmaceutical company headquartered at its manufacturing complex in Dhulivita, Dhamrai, approximately 40 kilometres northwest of Dhaka, Bangladesh. The company operates within the ACME Group of Companies and is associated with the production and export of pharmaceutical products. Its corporate history began in 1954, when the business was established as a partnership. In 1976, it was reorganized as a private limited company, marking a transition toward a more formal corporate structure. The company subsequently developed and modernized its manufacturing capabilities, beginning commercial operations at a technologically upgraded plant in 1983. The business passed its golden jubilee in 1995, reflecting more than four decades of operation in Bangladesh's pharmaceutical sector. Its later development included an effort to expand beyond the domestic market. After receiving regulatory approval in March 2019, Acme Laboratories began exporting pharmaceutical products to the United Kingdom in December of that year. In 2020, it entered the United States market through exports of zolpidem, a generic medicine used as a sleep aid. These exports represented an internationalization of the company beyond its established Bangladeshi base. Acme has also invested in pharmaceutical manufacturing infrastructure. By March 2023, it had established a facility in the Active Pharmaceutical Ingredients Industrial Park in Gazaria Upazila, Munshiganj District. The new site was intended to support API manufacturing, although production had not begun for at least a year because the plant lacked a natural-gas connection. Titas Gas attributed the delay to inadequate gas supply. The episode illustrates the infrastructure and utility constraints that can affect pharmaceutical capacity expansion in Bangladesh. The company is led by managing director Mizanur Rahman Sinha, who is also identified as its largest shareholder, while Nagina Afzal Sinha serves as chairperson. Publicly available reference material identifies Acme Laboratories primarily as a pharmaceutical manufacturer rather than as a consumer-facing product brand. Detailed information on its full product portfolio, revenue, workforce, ownership structure beyond the principal shareholder, and current production footprint is not established in the supplied sources.
History
Acme Laboratories was established in Bangladesh in 1954 as a partnership. The enterprise later adopted a private limited company structure in 1976. This reorganization preceded a period of manufacturing development, culminating in commercial operations at a modernized plant equipped with more advanced facilities in 1983. The company marked its golden jubilee in 1995. Its subsequent history included the development of export capabilities and efforts to meet the requirements of overseas pharmaceutical markets. Following regulatory approval obtained in March 2019, Acme began exporting to the United Kingdom in December 2019. The company entered the United States market the following year, exporting zolpidem as a generic sleeping medicine. Acme's principal plant is located at Dhulivita in Dhamrai, around 40 kilometres northwest of Dhaka. The company also expanded its infrastructure through a facility in the Active Pharmaceutical Ingredients Industrial Park in Gazaria Upazila, Munshiganj District. By March 2023, the plant had been set up, but manufacturing had not commenced because the site lacked a natural-gas connection. Titas Gas attributed the delay to an insufficient gas supply. The facility and its delayed start illustrate the operational infrastructure issues that can influence pharmaceutical investment and production in Bangladesh. The company forms part of the ACME Group of Companies. Mizanur Rahman Sinha is identified as its managing director and largest shareholder, and Nagina Afzal Sinha as chairperson. The available reference material does not provide a complete account of the company's product portfolio, financial performance, employee base, or later corporate developments.
- 2023
API Industrial Park facility established
[1]The company had established a manufacturing facility in the API Industrial Park in Gazaria, although production was delayed by the absence of a natural-gas connection.
- 2020
United States market entry
[1]Acme entered the United States market by exporting generic zolpidem.
- 2019
United Kingdom export expansion
[1]After receiving regulatory approval in March, Acme began exporting pharmaceutical products to the United Kingdom in December.
- 1995
Golden jubilee
[1]The company reached its fiftieth anniversary.
- 1983
Modernized plant begins commercial operations
[1]Commercial production commenced at a modernized facility equipped with more advanced manufacturing infrastructure.
- 1976
Converted to a private limited company
[1]The business changed from a partnership into a private limited company.
- 1954
Business established
[1]Acme Laboratories began operations as a partnership in Bangladesh.
Products and positioning
A Bangladesh-based pharmaceutical manufacturer with domestic production capabilities and export activity in regulated international markets.
Pharmaceuticals
Generic pharmaceutical medicines
Acme Laboratories is described as a pharmaceutical manufacturer producing medicines for the Bangladeshi market and for export. The supplied reference does not enumerate the company's complete therapeutic portfolio or individual branded product lines.
Generic prescription medicine · 2020
Zolpidem
Zolpidem is a generic sleep medication exported by Acme Laboratories to the United States after the company entered that market in 2020. The available material identifies the product and its export destination but does not specify a brand name, dosage range, or complete regulatory history.
Pharmaceutical manufacturing inputs · 2023
Active pharmaceutical ingredients
Acme established a facility in Bangladesh's Active Pharmaceutical Ingredients Industrial Park in Gazaria. The site was intended to support API-related production, but the supplied source states that operations were delayed by the lack of a natural-gas connection.
Brand decisions
2023
Development of an API manufacturing facilityStrategyBackground
Acme sought to expand pharmaceutical manufacturing infrastructure through a plant in the API Industrial Park in Gazaria Upazila, Munshiganj District.
Action taken
The company established the facility, but production could not begin for a year because the site lacked a natural-gas connection.
Aftermath
The start of production was delayed. Titas Gas attributed the problem to insufficient gas supply.
2020
Entry into the United States marketStrategyBackground
Following its United Kingdom export initiative, Acme sought to extend its international pharmaceutical business to the United States.
Action taken
The company exported generic zolpidem to the United States.
Aftermath
The export marked Acme's entry into the United States market, although the supplied material gives no further information about scale or subsequent product expansion.
2019
Expansion into the United KingdomStrategyBackground
Acme pursued access to an overseas regulated pharmaceutical market after operating primarily from its Bangladeshi manufacturing base.
Action taken
The company obtained regulatory approval in March 2019 and began exports to the United Kingdom in December.
Aftermath
The move established the United Kingdom as an identified export market for Acme Laboratories.
Recent events
- 2023
API facility expansion delayed by lack of natural-gas connection[1]
Other · Regulation
Although Acme had established a plant in the API Industrial Park in Gazaria by March 2023, production reportedly remained stalled for a year because the facility lacked a natural-gas connection. Titas Gas cited insufficient gas supply.
- 2020
Acme Laboratories enters the United States market with zolpidem exports[1]
Other · Product launch
Acme Laboratories expanded into the United States through exports of zolpidem, a generic sleeping tablet.
- 2019
Acme Laboratories receives approval to export pharmaceutical products to the United Kingdom[1]
Other
The company obtained regulatory approval in March 2019 and began exporting to the United Kingdom in December of the same year.
Sources1 sources
Cite this profile: Cite the canonical profile. /brand-wiki/acme-laboratories · Editorial policy · How profiles are compiled